Neuroscience
Neuroscience discovery and development
Exploring potential disease-modifying approaches
Researching symptom control
At Genventis, we are dedicated to advancing innovative treatments for neurological and neurodegenerative disorders through a translational approach that connects discovery science with clinical development. Our mission is to address both the underlying biology and the clinical manifestations of diseases affecting the central and peripheral nervous systems.
Our neuroscience programs focus on uncovering novel therapeutic targets and advancing early discovery platforms designed to restore or protect neuronal function. Genventis integrates cutting-edge molecular biology, biomarker discovery, and translational research to accelerate the path from lab findings to clinical proof of concept. Through collaboration with academic and clinical partners, we work to identify pathways that drive neuroinflammation, synaptic dysfunction, and neurodegeneration.
We are pursuing strategies aimed at changing the course of neurological diseases rather than managing symptoms alone. This includes investigating mechanisms of neuroprotection, synaptic repair, and immune modulation that could slow or halt disease progression. By leveraging biomarkers and precision medicine, Genventis seeks to identify patient populations most likely to benefit from disease-modifying interventions.
While developing transformative treatments remains our long-term goal, we also recognize the importance of improving patients’ daily lives through better symptom management. Genventis is evaluating therapies that target cognitive, motor, and behavioral symptoms, using both pharmacologic and non-pharmacologic approaches—to help patients maintain independence, functionality, and quality of life throughout the course of their disease.
Our focus on neurological disorders research
Our scientists are dedicated to discovering and developing novel therapeutics for a broad range of nervous system disorders—conditions that continue to pose significant medical and societal challenges. Through innovative research and a deep understanding of neurobiology, we aim to advance transformative treatments that improve patient outcomes.
Advancing Clinical Research Through Standardization
Big Data and a World of Possibilities
The BMT CTN is one of our longest-running, most collaborative and complex research partnerships.
Since 2023, in our role as the Center for Clinical Research Resources, we’ve supported the Common Data Elements (CDEs) program sponsored by the National Institute of Neurological Disorders and Stroke (NINDS).
The program will “standardize the collection of investigational data to facilitate comparison of results across studies and more effectively aggregate information into significant metadata results.”
Our key focus is to create common definitions and metadata which enable data sharing among researchers.
We’re helping NINDS to manage the process and work groups to establish CDEs. We also develop, manage and maintain the NINDS CDE website and database, allowing thousands of researchers worldwide access to information on neurological conditions including general, neuromuscular, stroke, and traumatic brain injury disorders. We’ve grown the number of CDEs in the NINDS’ program to 8,000 across 24 neurological disorders, and there’s still more we can do.
Related links
Vaccines
We’ve been discovering, developing, supplying and delivering vaccines to help prevent disease for over 130 years.
Oncology
Our teams of researchers and scientists are pushing the boundaries of cancer research to discover more effective anticancer therapies.
Neurosciece
Our science-led strategy is key to delivering long-term value for patients, employees, and shareholders.